Elevation Point Wealth Partners LLC Acquires Shares of 51,158 Abbott Laboratories $ABT

Key Points

• Elevation Point Wealth Partners acquired 51,158 Abbott Laboratories shares worth approximately $4.64 million in the second quarter. Other institutions also initiated positions, with institutional investors now owning 75.18% of ABT.
• Abbott reported quarterly EPS of $1.31 and revenue of $12.59 billion, surpassing analyst estimates, while revenue increased 13% year over year. The company issued 2026 EPS guidance of $5.45–$5.60.
• Analyst sentiment remains positive, with a consensus rating of “Moderate Buy” and an average price target of $119.50. Abbott also maintains a quarterly dividend of $0.63 per share, yielding about 2.3%.

Elevation Point Wealth Partners LLC bought a new position in Abbott Laboratories (NYSE:ABT - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 51,158 shares of the healthcare product maker's stock, valued at approximately $4,642,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Daiichi Life Insurance Co. Ltd. purchased a new position in shares of Abbott Laboratories in the 2nd quarter worth about $9,027,000. Foyston Gordon & Payne Inc purchased a new stake in Abbott Laboratories during the 2nd quarter valued at about $1,107,000. Commerce Bank bought a new stake in Abbott Laboratories during the 2nd quarter valued at about $40,622,000. Northwestern Mutual Wealth Management Co. purchased a new position in Abbott Laboratories in the second quarter worth about $23,165,000. Finally, Quantbot Technologies LP bought a new position in shares of Abbott Laboratories in the second quarter worth approximately $2,900,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Price Performance

Shares of ABT opened at $110.48 on Tuesday. The firm has a fifty day simple moving average of $103.06 and a two-hundred day simple moving average of $100.13. The firm has a market cap of $191.17 billion, a PE ratio of 35.75, a P/E/G ratio of 2.18 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company's revenue for the quarter was up 13.0% on a year-over-year basis. During the same period last year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories's dividend payout ratio is presently 81.55%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ABT. TD Cowen raised their price target on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a "buy" rating in a research report on Tuesday, August 25th. Bank of America lowered their price objective on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Wolfe Research raised Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 target price for the company in a report on Thursday, August 13th. Piper Sandler restated an "overweight" rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, JPMorgan Chase & Co. upped their price target on Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $119.50.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source